Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer
Status: TERMINATED
Study type: OBSERVATIONAL
Conditions: HER2-positive Metastatic Breast Cancer
Interventions: DRUG: KN026 combined with Palbociclib and Fulvestrant
Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd